<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198509</url>
  </required_header>
  <id_info>
    <org_study_id>09-0658</org_study_id>
    <secondary_id>RC2AR058986</secondary_id>
    <nct_id>NCT01198509</nct_id>
  </id_info>
  <brief_title>Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)</brief_title>
  <official_title>Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis (RA) is an inflammatory form of arthritis that causes joint pain and
      damage. RA attacks the lining of the joints (synovium), causing swelling that can result in
      aching and throbbing, and eventually deformity. Even though there have been many advances in
      the treatment of RA, psoriatic arthritis (PsA), and other inflammatory arthritis, doctors
      still do not know what causes this inflammation in joints. It is likely that RA occurs as a
      result of a complex combination of factors, including a person's genes; lifestyle choices,
      such as smoking and diet; and things in a person's environment, including bacteria or
      viruses. This study investigates the hypothesis that bacteria living in a person's mouth
      and/or intestinal tract are responsible, at least in part, for the development of Rheumatoid
      Arthritis. The investigators believe that by killing those bacteria with antibiotics, they
      might be able to understand how the immune system works and, maybe, what causes RA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      If you would like to participate in this study, we will first ask you several questions
      regarding the status of your arthritis, the medications you use or have used in the recent
      past, your social and dietary habits, and your medical and surgical history. If your answers
      tell us that you are the right patient for our study, we will go over a consent form which
      describes in more detail how we will study your intestinal and mouth bacteria, the immune
      cells in your blood and other genes, enzymes and proteins that tell us about your disease
      status.

      If you have Psoriatic Arthritis (PsA) or are healthy with no history of arthritis, and would
      like to participate in this study, your participation would involve only one or two visits,
      and no treatment.

      If you have Rheumatoid Arthritis (RA), your participation would involve six visits, and you
      would be randomly assigned to receive treatment with the antibiotic doxycycline, or the
      antibiotic vancomycin, or no antibiotic treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alteration of Microbiota, Alteration of T Cell Function/Activation</measure>
    <time_frame>6 months</time_frame>
    <description>Oral and intestinal microbiota, and T cell function and activation, will be assessed at baseline, and at 1, 2, 3, 4 and 5 months after baseline, to determine whether changes are associated with vancomycin treatment versus doxycycline treatment versus no treatment.
Results are reported as number of participants who experienced changes in oral/intestinal microbiota, T cell function/activation.
Methods/criteria to assess change in microbiota: change in relative abundance of microorganisms at genus and species level (as assessed high-throughput 16S rDNA sequencing).
Methods/criteria to assess change in T cell function/activation: change in percentage of inhibition of regulatory T cells as measured by interferon gamma levels in in-vitro assays.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Units Change in DAS28 From Baseline to 6 Months</measure>
    <time_frame>6 months</time_frame>
    <description>DAS28 (disease activity score with 28 joint count). Possible score range: 0 to 10. This is a composite index calculated from 4 measures: two from a physician (28 tender joint count, 28 swollen joint count), one from the patient (patient global estimate of disease activity), and one laboratory biomarker (erythrocyte sedimentation rate or ESR). A score of 0 represents best possible health status (no apparent disease activity) and 10 represents worst possible.
The outcome is reported as mean change in DAS28 score from baseline to 6 months. The mean changes reported are negative values for downward change in score (i.e., improvement in health status).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">178</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Psoriatic Arthritis</condition>
  <condition>Periodontal Disease</condition>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis (RA) - doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive doxycycline, 100 mg twice a day, for 2 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rheumatoid Arthritis (RA) - vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive vancomycin, 250 mg four times a day, for 2 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RA, PsA, healthy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive no antibiotic treatment for comparison with Doxycycline- and Vancomycin-treated patients.
Patients with psoriatic arthritis (PsA), to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.
Healthy individuals with no history of arthritis, to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline</intervention_name>
    <description>doxycycline - 100 mg twice per day, for 2 months</description>
    <arm_group_label>Rheumatoid Arthritis (RA) - doxycycline</arm_group_label>
    <other_name>Vibramycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vancomycin</intervention_name>
    <description>vancomycin, 250 mg four times a day, for 2 weeks</description>
    <arm_group_label>Rheumatoid Arthritis (RA) - vancomycin</arm_group_label>
    <other_name>Vancocin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Rheumatoid Arthritis (RA) patients must meet American College of Rheumatology (ACR)
             criteria for RA

          -  RA patients: duration of disease will be greater than 6 weeks and less than 2 years.

          -  RA patients should have a Disease Activity Score 28 (DAS28) greater than or equal to
             5.

          -  PsA patients will be required to have disease duration and DAS28 similar to the RA
             patients, and to meet Moll and Wright criteria for PsA.

          -  Allowable medications for both groups at study entry will include: prednisone (or
             equivalent) 5 mg or less per day (stable dose for at least 2 months); methotrexate 15
             mg or less per week (stable dose for at least 2 months); and nonsteroidal
             anti-inflammatory drugs (NSAIDs) at FDA-approved doses.

          -  Healthy controls will be age- and sex-matched individuals with no personal or family
             history of inflammatory arthritis.

        Exclusion Criteria:

          -  Patients who are unable to provide informed consent.

          -  Pregnant or lactating women.

          -  Recent (&lt;3 months prior) use of any antibiotic therapy

          -  Current consumption of probiotics

          -  Current extreme diet (parenteral nutrition, macrobiotic diet, etc.)

          -  Prednisone &gt;5 mg/day or equivalent

          -  Use of other disease-modifying antirheumatic drugs (DMARDs) with known antibiotic
             properties (Gold salts, hydroxychloroquine, sulfasalazine or minocycline).

          -  Use of biologic DMARDs

          -  Known inflammatory bowel disease

          -  Known gastrointestinal (GI) tract neoplasm.

          -  Recent GI tract infection (gastroenteritis, colitis, diverticulitis, appendicitis)

          -  Chronic unexplained diarrhea.

          -  Any GI tract surgery leaving permanent residua (e.g., gastrectomy; bariatric surgery;
             colectomy)

          -  Significant liver, renal or peptic ulcer disease, defined as:

               -  Liver: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) &gt; 2 x
                  upper limit of normal (ULN)

               -  Renal: Creatinine &gt;1.5 or endstage renal disease

               -  Peptic ulcer disease: recent ulcer or GI bleed (within past 12 months)

          -  Inability or unwillingness to abstain from alcohol consumption.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven B. Abramson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose U. Scher, MD</last_name>
    <role>Study Director</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU Hospital for Joint Diseases</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Scher JU, Abramson SB. The microbiome and rheumatoid arthritis. Nat Rev Rheumatol. 2011 Aug 23;7(10):569-78. doi: 10.1038/nrrheum.2011.121. Review.</citation>
    <PMID>21862983</PMID>
  </reference>
  <reference>
    <citation>Honda K, Littman DR. The microbiome in infectious disease and inflammation. Annu Rev Immunol. 2012;30:759-95. doi: 10.1146/annurev-immunol-020711-074937. Epub 2012 Jan 6. Review.</citation>
    <PMID>22224764</PMID>
  </reference>
  <reference>
    <citation>Littman DR, Pamer EG. Role of the commensal microbiota in normal and pathogenic host immune responses. Cell Host Microbe. 2011 Oct 20;10(4):311-23. doi: 10.1016/j.chom.2011.10.004. Review.</citation>
    <PMID>22018232</PMID>
  </reference>
  <reference>
    <citation>Brusca SB, Abramson SB, Scher JU. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr Opin Rheumatol. 2014 Jan;26(1):101-7. doi: 10.1097/BOR.0000000000000008. Review.</citation>
    <PMID>24247114</PMID>
  </reference>
  <reference>
    <citation>Scher JU, Abramson SB. Periodontal disease, Porphyromonas gingivalis, and rheumatoid arthritis: what triggers autoimmunity and clinical disease? Arthritis Res Ther. 2013;15(5):122.</citation>
    <PMID>24229458</PMID>
  </reference>
  <results_reference>
    <citation>Scher JU, Ubeda C, Equinda M, Khanin R, Buischi Y, Viale A, Lipuma L, Attur M, Pillinger MH, Weissmann G, Littman DR, Pamer EG, Bretz WA, Abramson SB. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. 2012 Oct;64(10):3083-94. doi: 10.1002/art.34539.</citation>
    <PMID>22576262</PMID>
  </results_reference>
  <results_reference>
    <citation>Tang W, Lu Y, Tian QY, Zhang Y, Guo FJ, Liu GY, Syed NM, Lai Y, Lin EA, Kong L, Su J, Yin F, Ding AH, Zanin-Zhorov A, Dustin ML, Tao J, Craft J, Yin Z, Feng JQ, Abramson SB, Yu XP, Liu CJ. The growth factor progranulin binds to TNF receptors and is therapeutic against inflammatory arthritis in mice. Science. 2011 Apr 22;332(6028):478-84. doi: 10.1126/science.1199214. Epub 2011 Mar 10.</citation>
    <PMID>21393509</PMID>
  </results_reference>
  <results_reference>
    <citation>Scher JU, Sczesnak A, Longman RS, Segata N, Ubeda C, Bielski C, Rostron T, Cerundolo V, Pamer EG, Abramson SB, Huttenhower C, Littman DR. Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. Elife. 2013 Nov 5;2:e01202. doi: 10.7554/eLife.01202.</citation>
    <PMID>24192039</PMID>
  </results_reference>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2010</study_first_submitted>
  <study_first_submitted_qc>September 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <results_first_submitted>September 3, 2014</results_first_submitted>
  <results_first_submitted_qc>December 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 13, 2015</results_first_posted>
  <last_update_submitted>December 31, 2014</last_update_submitted>
  <last_update_submitted_qc>December 31, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rheumatoid arthritis</keyword>
  <keyword>psoriatic arthritis</keyword>
  <keyword>periodontitis</keyword>
  <keyword>microbiota</keyword>
  <keyword>microbiome</keyword>
  <keyword>vancomycin</keyword>
  <keyword>doxycycline</keyword>
  <keyword>T cell</keyword>
  <keyword>Th17</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Gingival Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates of recruitment period: January 2010 - August 2012 Locations: Medical clinics and faculty practice offices</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rheumatoid Arthritis (RA) - Doxycycline</title>
          <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive doxycycline, 100 mg twice a day, for 2 months.
doxycycline: doxycycline - 100 mg twice per day, for 2 months
N=5 (actual)</description>
        </group>
        <group group_id="P2">
          <title>Rheumatoid Arthritis (RA) - Vancomycin</title>
          <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive vancomycin, 250 mg four times a day, for 2 weeks
vancomycin: vancomycin, 250 mg four times a day, for 2 weeks
N=10 (actual)</description>
        </group>
        <group group_id="P3">
          <title>Rheumatoid Arthritis (RA) Randomized to no Treatment</title>
          <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive no antibiotic treatment for comparison with Doxycycline- and Vancomycin-treated patients.
N=19 (actual)</description>
        </group>
        <group group_id="P4">
          <title>Early RA Cross-sectional Cohort</title>
          <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria who opted to participate ONLY in cross-sectional analysis (one-time sample collection equivalent to the involvement of PsA and health control subjects).
N=66 (actual)</description>
        </group>
        <group group_id="P5">
          <title>Psoriatic Arthritis (PsA)</title>
          <description>Patients with psoriatic arthritis (PsA), to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.
N=20 (actual)</description>
        </group>
        <group group_id="P6">
          <title>Healthy Volunteers</title>
          <description>Healthy individuals with no history of arthritis, to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.
N=58 (actual)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="66"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4">Patient declined further participation after enrollment and allocation to treatment group</participants>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="66"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rheumatoid Arthritis (RA) - Doxycycline</title>
          <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive doxycycline, 100 mg twice a day, for 2 months.
doxycycline: doxycycline - 100 mg twice per day, for 2 months</description>
        </group>
        <group group_id="B2">
          <title>Rheumatoid Arthritis (RA) - Vancomycin</title>
          <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive vancomycin, 250 mg four times a day, for 2 weeks
vancomycin: vancomycin, 250 mg four times a day, for 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Rheumatoid Arthritis (RA) Randomized to no Treatment</title>
          <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive no antibiotic treatment and followed prospectively for 6 months, for comparison with Doxycycline- and Vancomycin-treated patients.</description>
        </group>
        <group group_id="B4">
          <title>Early RA Cross-sectional Cohort</title>
          <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria who opted to participate ONLY in cross-sectional analysis (one-time sample collection equivalent to the involvement of PsA and health control subjects).</description>
        </group>
        <group group_id="B5">
          <title>Psoriatic Arthritis (PsA)</title>
          <description>Patients with psoriatic arthritis (PsA), to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.</description>
        </group>
        <group group_id="B6">
          <title>Healthy Volunteers</title>
          <description>Healthy individuals with no history of arthritis, to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="19"/>
            <count group_id="B4" value="66"/>
            <count group_id="B5" value="20"/>
            <count group_id="B6" value="58"/>
            <count group_id="B7" value="178"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.0" lower_limit="31" upper_limit="68"/>
                    <measurement group_id="B2" value="41.5" lower_limit="24" upper_limit="63"/>
                    <measurement group_id="B3" value="39.2" lower_limit="26" upper_limit="69"/>
                    <measurement group_id="B4" value="49.1" lower_limit="20" upper_limit="85"/>
                    <measurement group_id="B5" value="45.5" lower_limit="26" upper_limit="73"/>
                    <measurement group_id="B6" value="40.7" lower_limit="21" upper_limit="62"/>
                    <measurement group_id="B7" value="44.2" lower_limit="20" upper_limit="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="58"/>
                    <measurement group_id="B7" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="50"/>
                    <measurement group_id="B7" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="29"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="35"/>
                    <measurement group_id="B7" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="43"/>
                    <measurement group_id="B7" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="66"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="58"/>
                    <measurement group_id="B7" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Alteration of Microbiota, Alteration of T Cell Function/Activation</title>
        <description>Oral and intestinal microbiota, and T cell function and activation, will be assessed at baseline, and at 1, 2, 3, 4 and 5 months after baseline, to determine whether changes are associated with vancomycin treatment versus doxycycline treatment versus no treatment.
Results are reported as number of participants who experienced changes in oral/intestinal microbiota, T cell function/activation.
Methods/criteria to assess change in microbiota: change in relative abundance of microorganisms at genus and species level (as assessed high-throughput 16S rDNA sequencing).
Methods/criteria to assess change in T cell function/activation: change in percentage of inhibition of regulatory T cells as measured by interferon gamma levels in in-vitro assays.</description>
        <time_frame>6 months</time_frame>
        <population>Primary outcome only evaluated in first three groups of RA patients: 4 randomized to treatment with doxycycline; 10 randomized to treatment with vancomycin; 19 randomized to no treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis (RA) - Doxycycline</title>
            <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive doxycycline, 100 mg twice a day, for 2 months.
doxycycline: doxycycline - 100 mg twice per day, for 2 months</description>
          </group>
          <group group_id="O2">
            <title>Rheumatoid Arthritis (RA) - Vancomycin</title>
            <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive vancomycin, 250 mg four times a day, for 2 weeks
vancomycin: vancomycin, 250 mg four times a day, for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Rheumatoid Arthritis (RA) Randomized to no Treatment</title>
            <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive no antibiotic treatment, followed prospectively for 6 months, for comparison with Doxycycline- and Vancomycin-treated patients.
N=19 (actual)</description>
          </group>
          <group group_id="O4">
            <title>Early RA Cross-sectional Cohort</title>
            <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria who opted to participate ONLY in cross-sectional analysis (one-time sample collection equivalent to the involvement of PsA and health control subjects).
N=66 (actual)</description>
          </group>
          <group group_id="O5">
            <title>Psoriatic Arthritis (PsA)</title>
            <description>Patients with psoriatic arthritis (PsA), to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.
N=20 (actual)</description>
          </group>
          <group group_id="O6">
            <title>Healthy Volunteers</title>
            <description>Healthy individuals with no history of arthritis, to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.
N=58 (actual)</description>
          </group>
        </group_list>
        <measure>
          <title>Alteration of Microbiota, Alteration of T Cell Function/Activation</title>
          <description>Oral and intestinal microbiota, and T cell function and activation, will be assessed at baseline, and at 1, 2, 3, 4 and 5 months after baseline, to determine whether changes are associated with vancomycin treatment versus doxycycline treatment versus no treatment.
Results are reported as number of participants who experienced changes in oral/intestinal microbiota, T cell function/activation.
Methods/criteria to assess change in microbiota: change in relative abundance of microorganisms at genus and species level (as assessed high-throughput 16S rDNA sequencing).
Methods/criteria to assess change in T cell function/activation: change in percentage of inhibition of regulatory T cells as measured by interferon gamma levels in in-vitro assays.</description>
          <population>Primary outcome only evaluated in first three groups of RA patients: 4 randomized to treatment with doxycycline; 10 randomized to treatment with vancomycin; 19 randomized to no treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change in oral/intestinal microbiota</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in T cell function/activation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Units Change in DAS28 From Baseline to 6 Months</title>
        <description>DAS28 (disease activity score with 28 joint count). Possible score range: 0 to 10. This is a composite index calculated from 4 measures: two from a physician (28 tender joint count, 28 swollen joint count), one from the patient (patient global estimate of disease activity), and one laboratory biomarker (erythrocyte sedimentation rate or ESR). A score of 0 represents best possible health status (no apparent disease activity) and 10 represents worst possible.
The outcome is reported as mean change in DAS28 score from baseline to 6 months. The mean changes reported are negative values for downward change in score (i.e., improvement in health status).</description>
        <time_frame>6 months</time_frame>
        <population>Please note that only the first 3 groups (RA doxycycline, RA vancomycin, and RA randomized to no treatment) were analyzed for change from baseline to six months (outcomes). Groups 4, 5 and 6 (RA cross-sectional, Psoriatic Arthritis, and Healthy Volunteers) were analyzed for baseline measures only in a cross-sectional comparison.</population>
        <group_list>
          <group group_id="O1">
            <title>Rheumatoid Arthritis (RA) - Doxycycline</title>
            <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive doxycycline, 100 mg twice a day, for 2 months.
doxycycline: doxycycline - 100 mg twice per day, for 2 months</description>
          </group>
          <group group_id="O2">
            <title>Rheumatoid Arthritis (RA) - Vancomycin</title>
            <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive vancomycin, 250 mg four times a day, for 2 weeks
vancomycin: vancomycin, 250 mg four times a day, for 2 weeks</description>
          </group>
          <group group_id="O3">
            <title>Rheumatoid Arthritis (RA) Randomized to no Treatment</title>
            <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive no antibiotic treatment and followed prospectively for 6 months, for comparison with Doxycycline- and Vancomycin-treated patients.
N=19 (actual)</description>
          </group>
          <group group_id="O4">
            <title>Early RA Cross-sectional Cohort</title>
            <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria who opted to participate ONLY in cross-sectional analysis (one-time sample collection equivalent to the involvement of PsA and health control subjects).
N=66 (actual)</description>
          </group>
          <group group_id="O5">
            <title>Psoriatic Arthritis (PsA)</title>
            <description>Patients with psoriatic arthritis (PsA), to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.
N=20 (actual)</description>
          </group>
          <group group_id="O6">
            <title>Healthy Volunteers</title>
            <description>Healthy individuals with no history of arthritis, to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.
N=58 (actual)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Units Change in DAS28 From Baseline to 6 Months</title>
          <description>DAS28 (disease activity score with 28 joint count). Possible score range: 0 to 10. This is a composite index calculated from 4 measures: two from a physician (28 tender joint count, 28 swollen joint count), one from the patient (patient global estimate of disease activity), and one laboratory biomarker (erythrocyte sedimentation rate or ESR). A score of 0 represents best possible health status (no apparent disease activity) and 10 represents worst possible.
The outcome is reported as mean change in DAS28 score from baseline to 6 months. The mean changes reported are negative values for downward change in score (i.e., improvement in health status).</description>
          <population>Please note that only the first 3 groups (RA doxycycline, RA vancomycin, and RA randomized to no treatment) were analyzed for change from baseline to six months (outcomes). Groups 4, 5 and 6 (RA cross-sectional, Psoriatic Arthritis, and Healthy Volunteers) were analyzed for baseline measures only in a cross-sectional comparison.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-1.7" upper_limit="-0.4"/>
                    <measurement group_id="O2" value="-1.5" lower_limit="-4.4" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="-2.5" lower_limit="-3.9" upper_limit="-0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Duration of the study, up to 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rheumatoid Arthritis (RA) - Doxycycline</title>
          <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive doxycycline, 100 mg twice a day, for 2 months.
doxycycline: doxycycline - 100 mg twice per day, for 2 months</description>
        </group>
        <group group_id="E2">
          <title>Rheumatoid Arthritis (RA) - Vancomycin</title>
          <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive vancomycin, 250 mg four times a day, for 2 weeks
vancomycin: vancomycin, 250 mg four times a day, for 2 weeks</description>
        </group>
        <group group_id="E3">
          <title>RA, PsA, Healthy</title>
          <description>Patients with rheumatoid arthritis (RA) meeting inclusion criteria, randomized to receive no antibiotic treatment for comparison with Doxycycline- and Vancomycin-treated patients.
Patients with psoriatic arthritis (PsA), to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.
Healthy individuals with no history of arthritis, to provide baseline samples of oral and intestinal microbiota for comparison with RA patients.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Other</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>stomach pain/loose stools</sub_title>
                <description>Resolved within 24 hours. Possibly related to study treatment. Participant continued treatment and completed study.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Interpretation of results is limited by very small sample size. It should be noted that this was intended as a proof-of-concept study, and not a fully-powered clinical trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Steven B. Abramson, MD</name_or_title>
      <organization>New York University School of Medicine</organization>
      <phone>212-263-8003</phone>
      <email>StevenB.Abramson@nyumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

